Back to discover
Disease

Phobic Disorders

Late-stage therapeutic developmentEmerging research
MeSHPhobic Disorders
1
Publications
7
Clinical trials
9
Associated genes
1
Related proteins
2023
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

No activity recorded in this window. Try a wider timeframe.

Clinical trials

7 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
7
All trials
0
Active
3
Late-stage
6
Completed
Recently completed

A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Efficacy, Safety, and Tolerability of JNJ-42165279 in Subjects With Social Anxiety Disorder.

Phase 2 · Completed · Janssen Research & Development, LLC

Effect of D-Cycloserine on Treatment of Social Phobia

Phase 2 · Completed · National Institute of Mental Health (NIMH)

Evaluation of the Effects of Post-Session Administration of D-cycloserine On Exposure Therapy Outcomes

Phase 3 · Completed · Southern Methodist University

A Randomised, Triple Blind, Placebo-controlled Trial Comparing the Effects of Cognitive Therapy, Paroxetine and Both Cognitive Therapy and Paroxetine in the Treatment of Patients With Primary Social Phobia

Phase 4 · Completed · Norwegian University of Science and Technology

Placebo-Controlled Pilot Study of Escitalopram in the Treatment of Specific Phobia

Phase 2/3 · Completed · Connor, Kathryn M., M.D.

St. John's Wort Versus Placebo in Social Phobia

Phase 2 · Completed · National Center for Complementary and Integrative Health (NCCIH)

Research activity

1 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Major themes3
  • Major Depressive Disorder1
  • Mental Disorders1
  • Phobic Disorders1
Leading journals1
  • The lancet. Psychiatry1
Leading researchers8
  • Al-Hamzawi A1
  • Alonso J1
  • Altwaijri Y1
  • Andrade LH1
  • Bromet EJ1
  • Bruffaerts R1
  • Chardoul S1
  • Chiu WT1
Affiliations (unnormalised)6
  • Brigham and Women's Hospital1
  • Center for Excellence on Research in Mental Health1
  • Colegio Mayor de Cundinamarca University1
  • College of Medicine1
  • Department of Psychiatry and Clinical Psychology1
  • Graduate School of Medicine1

Associated genes

9 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

KCNK100.29JPH10.28CMKLR10.25ZC3H12A0.25ALPG0.20TAF5L0.17ACTR3B0.16ENTPD20.14URB20.06

Disease biology

1 match

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Potassium channel subfamily K member 10via KCNK100.29

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Anxiety disorders in which the essential feature is persistent and irrational fear of a specific object, activity, or situation that the individual feels compelled to avoid.

Identifiers
MeSHPhobic Disorders
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.